C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...

Atea Pharmaceuticals offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines the advantages of current first-line HCV therapies—single pill ...

"With 2 pivotal Phase III top line readouts for our global Phase III HCV program ahead of us, 2026 will be a catalyst-rich year for Atea" (Founder, Chairman, CEO & President Jean-Pierre Sommadossi).

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...

Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...

Please provide your email address to receive an email when new articles are posted on . More frequent HCV testing was cost-effective among people who inject drugs in both high- and low-transmission ...